Personalized treatment of lymphoma: Promise and reality

Seminars in Oncology

Volumn 38, Issue 2, 2011, Pages 225-235

  Ramsdale, Erika ^a   Van Besien, Koen ^a   Smith, Sonali M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CANCER VACCINE; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ENZASTAURIN; ETOPOSIDE; EVEROLIMUS; FLUDARABINE; FLUORODEOXYGLUCOSE F 18; METHOTREXATE; MYVAX; PREDNISONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RITUXIMAB; TUMOR MARKER; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ARTICLE; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DRUG EFFICACY; EVENT FREE SURVIVAL; FOLLICULAR LYMPHOMA; GENE EXPRESSION PROFILING; GENE MUTATION; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; LARGE CELL LYMPHOMA; LYMPHOMA; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

CANCER VACCINES; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; INDIVIDUALIZED MEDICINE; LYMPHOMA; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, MANTLE-CELL; POSITRON-EMISSION TOMOGRAPHY;

EID: 79952937520     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2011.01.008     Document Type: Article

References (81)

1. S. Swerdlow, E. Campo, and N. Harris WHO classification of tumours of haematopoietic and lymphoid tissues (ed 4) 2008 IARC Press Lyon
2. P. Feugier, A. Van Hoof, and C. Sebban Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol 23 2005 4117 4126 (Pubitemid 46211317)
3. T.M. Habermann, E.A. Weller, and V.A. Morrison Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma J Clin Oncol 24 2006 3121 3127 (Pubitemid 46638950)
4. M. Pfreundschuh, L. Trumper, and A. Osterborg CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group Lancet Oncol 7 2006 379 391
5. L.H. Sehn, J. Donaldson, and M. Chhanabhai Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia J Clin Oncol 23 2005 5027 5033 (Pubitemid 46224009)
6. L.H. Sehn, B. Berry, and M. Chhanabhai The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP Blood 109 2007 1857 1861 (Pubitemid 46348180)
7. A predictive model for aggressive non-Hodgkin's lymphoma The International Non-Hodgkin's Lymphoma Prognostic Factors Project N Engl J Med 329 1993 987 994
8. M. Ziepert, D. Hasenclever, and E. Kuhnt Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era J Clin Oncol 28 2010 2373 2380
9. R.H. Advani, H. Chen, and T.M. Habermann Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI) Br J Haematol 151 2010 143 151
10. J. Iqbal, V.T. Neppalli, and G. Wright BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma J Clin Oncol 24 2006 961 968 (Pubitemid 46638851)
11. M. Crump, T. Baetz, and S. Couban Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) Cancer 101 2004 1835 1842 (Pubitemid 39314747)
12. N. Mounier, J. Briere, and C. Gisselbrecht Rituximab plus CHOP (R-CHOP) overcomes bcl-2 - associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL) Blood 101 2003 4279 4284 (Pubitemid 36857789)
13. J.N. Winter, E.A. Weller, and S.J. Horning Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study Blood 107 2006 4207 4213 (Pubitemid 43801342)
14. S. Barrans, S. Crouch, and A. Smith Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab J Clin Oncol 28 2010 3360 3365
15. W. Klapper, H. Stoecklein, and S. Zeynalova Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) Leukemia 22 2008 2226 2229
16. N. Niitsu, M. Okamoto, I. Miura, and M. Hirano Clinical significance of 8q24/c-MYC translocation in diffuse large B-cell lymphoma Cancer Sci 100 2008 233 237
17. K.J. Savage, N.A. Johnson, and S. Ben-Neriah MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy Blood 114 2009 3533 3537
18. A.A. Alizadeh, M.B. Eisen, and R.E. Davis Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 403 2000 503 511 (Pubitemid 30082188)
19. I.S. Lossos, D.K. Czerwinski, and A.A. Alizadeh Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes N Engl J Med 350 2004 1828 1837 (Pubitemid 38917249)
20. A. Rosenwald, G. Wright, and W.C. Chan The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma N Engl J Med 346 2002 1937 1947 (Pubitemid 34651353)
21. M.A. Shipp, K.N. Ross, and P. Tamayo Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning Nat Med 8 2002 68 74 (Pubitemid 34101731)
22. C.C. Chang, S. McClintock, and R.P. Cleveland Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma Am J Surg Pathol 28 2004 464 470 (Pubitemid 38436519)
23. C.P. Hans, D.D. Weisenburger, and T.C. Greiner Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray Blood 103 2004 275 282 (Pubitemid 38029949)
24. A.I. Saez, A.J. Saez, and M.J. Artiga Building an outcome predictor model for diffuse large B-cell lymphoma Am J Pathol 164 2004 613 622
25. H. Nyman, M. Adde, and M.L. Karjalainen-Lindsberg Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy Blood 109 2007 4930 4935 (Pubitemid 46827791)
26. G. Ott, M. Ziepert, and W. Klapper Immunoblastic morphology but not the immunohistochemical GCB/non-GCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL Blood 116 2010 4916 4925
27. P. Solal-Celigny, P. Roy, and P. Colombat Follicular lymphoma international prognostic index Blood 104 2004 1258 1265 (Pubitemid 39166497)
28. G. Perea, A. Altes, and S. Montoto Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems Ann Oncol 16 2005 1508 1513 (Pubitemid 41222424)
29. C. Buske, E. Hoster, M. Dreyling, J. Hasford, M. Unterhalt, and W. Hiddemann The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome Blood 108 2006 1504 1508 (Pubitemid 44321768)
30. M. Federico, S. Molica, M. Bellei, and S. Luminari Prognostic factors in low-grade non-Hodgkin lymphomas Curr Hematol Malig Rep 4 2009 202 210
31. A.M. Glas, M.J. Kersten, and L.J. Delahaye Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment Blood 105 2005 301 307 (Pubitemid 40053097)
32. S.S. Dave, G. Wright, and B. Tan Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells N Engl J Med 351 2004 2159 2169 (Pubitemid 39507628)
33. P. Farinha, H. Masoudi, and B.F. Skinnider Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL) Blood 106 2005 2169 2174 (Pubitemid 41291735)
34. P. Farinha, A. Al-Tourah, K. Gill, R. Klasa, J.M. Connors, and R.D. Gascoyne The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation Blood 115 2010 289 295
35. B.E. Wahlin, M. Aggarwal, and S. Montes-Moreno A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1positive, regulatory, cytotoxic, and helper T cells and macrophages Clin Cancer Res 16 2010 637 650
36. M. Dreyling, E. Hoster, and S. Bea Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma (MCL): minutes of the 9th European MCL Network conference Leuk Lymphoma 51 2010 1612 1622
37. J. Orchard, R. Garand, and Z. Davis A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease Blood 101 2003 4975 4981 (Pubitemid 36857762)
38. E. Hoster, M. Dreyling, and W. Klapper A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma Blood 111 2008 558 565
39. O. Determann, E. Hoster, and G. Ott Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group Blood 111 2008 2385 2387 (Pubitemid 351451450)
40. T. Katzenberger, C. Petzoldt, and S. Holler The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma Blood 107 2006 3407
41. M. Tiemann, C. Schrader, and W. Klapper Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network Br J Haematol 131 2005 29 38 (Pubitemid 43899705)
42. A. Rosenwald, G. Wright, and A. Wiestner The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma Cancer Cell 3 2003 185 197 (Pubitemid 37443390)
43. E. Hartmann, V. Fernandez, and V. Moreno Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue J Clin Oncol 26 2008 4966 4972
44. M. Dreyling, G. Lenz, and E. Hoster Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network Blood 105 2005 2677 2684 (Pubitemid 40450320)
45. C.H. Geisler, A. Kolstad, and A. Laurell Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group Blood 112 2008 2687 2693
46. M. Ghielmini, and E. Zucca How I treat mantle cell lymphoma Blood 114 2009 1469 1476
47. I.F. Khouri, R.M. Saliba, G.J. Okoroji, S.A. Acholonu, and R.E. Champlin Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score Cancer 98 2003 2630 2635 (Pubitemid 37509526)
48. L.E. Damon, J.L. Johnson, and D. Niedzwiecki Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909 J Clin Oncol 27 2009 6101 6108
49. H. Schulz, J.F. Bohlius, and S. Trelle Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis J Natl Cancer Inst 99 2007 706 714 (Pubitemid 47078732)
50. L. Nogova, T. Rudiger, and A. Engert Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma Hematol Am Soc Hematol Educ Program 2006 266 272
51. D. Hasenclever, and V. Diehl A prognostic score for advanced Hodgkin's disease International Prognostic Factors Project on Advanced Hodgkin's Disease N Engl J Med 339 1998 1506 1514
52. A.K. Ng, M.P. Bernardo, and E. Weller Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger J Clin Oncol 20 2002 2101 2108 (Pubitemid 34408801)
53. Armitage JO. Early-stage Hodgkin's lymphoma. N Engl J Med;363:653-62.
54. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med;363:640-52.
55. G.P. Canellos, J.R. Anderson, and K.J. Propert Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD N Engl J Med 327 1992 1478 1484
56. V. Diehl, J. Franklin, and M. Pfreundschuh Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease N Engl J Med 348 2003 2386 2395 (Pubitemid 36682817)
57. A. Engert, V. Diehl, and J. Franklin Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study J Clin Oncol 27 2009 4548 4554
58. M.E. Juweid, S. Stroobants, and O.S. Hoekstra Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma J Clin Oncol 25 2007 571 578 (Pubitemid 350002965)
59. A. Gallamini, C. Stelitano, and R. Calvi Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study Blood 103 2004 2474 2479 (Pubitemid 38392996)
60. J.W. Friedberg, A. Fischman, and D. Neuberg FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison Leuk Lymphoma 45 2004 85 92 (Pubitemid 38181398)
61. M. Hutchings, A. Loft, and M. Hansen FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma Blood 107 2006 52 59 (Pubitemid 43053523)
62. M. Hutchings, N.G. Mikhaeel, P.A. Fields, T. Nunan, and A.R. Timothy Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma Ann Oncol 16 2005 1160 1168 (Pubitemid 41418320)
63. S. Querellou, F. Valette, and C. Bodet-Milin FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease Ann Hematol 85 2006 759 767 (Pubitemid 44377874)
64. P.L. Zinzani, M. Tani, and S. Fanti Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients Ann Oncol 17 2006 1296 1300 (Pubitemid 44288221)
65. B.D. Cheson, B. Pfistner, and M.E. Juweid Revised response criteria for malignant lymphoma J Clin Oncol 25 2007 579 586 (Pubitemid 350002966)
66. G. Jerusalem, Y. Beguin, and M.F. Fassotte Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging Blood 94 1999 429 433 (Pubitemid 29323856)
67. N.G. Mikhaeel, A.R. Timothy, S.F. Hain, and M.J. O'Doherty 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas Ann Oncol 11 Suppl 1 2000 147 150
68. K. Spaepen, and L. Mortelmans Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease Q J Nucl Med 45 2001 269 273 (Pubitemid 34182908)
69. 18F]fluoro-2-deoxy-D- glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome Blood 106 2005 1376 1381 (Pubitemid 41129604)
70. N.G. Mikhaeel Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: where are we now? Leuk Lymphoma 50 2009 1931 1936
71. C.H. Moskowitz, H. Schoder, and J. Teruya-Feldstein Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma J Clin Oncol 28 2010 1896 1903
72. H.S. Han, M.P. Escalon, B. Hsiao, A. Serafini, and I.S. Lossos High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens Ann Oncol 20 2009 309 318
73. M. Bendandi, C.D. Gocke, and C.B. Kobrin Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma Nat Med 5 1999 1171 1177 (Pubitemid 29474422)
74. J.M. Timmerman, D.K. Czerwinski, and T.A. Davis Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients Blood 99 2002 1517 126
75. F.J. Hsu, C.B. Caspar, and D. Czerwinski Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphomalong-term results of a clinical trial Blood 89 1997 3129 3135
76. A. Freedman, S.S. Neelapu, and C. Nichols Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma J Clin Oncol 27 2009 3036 3043
77. R. Levy, M.J. Robertson, K. Ganjoo, J.P. Leonard, J. Vose, and D. Denney Results of a phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin's lymphoma (fNHL) Proceedings of the 98th Annual Meeting of the American Assoc Cancer Res 2008 LB-204
78. S.J. Schuster, S.S. Neelapu, and B.L. Gause Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: phase III clinical trial results [abstract 2] J Clin Oncol 27 suppl 2009 18s
79. M. Bendandi Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures Nat Rev Cancer 9 2009 675 681
80. S.V. Sharma, and J. Settleman Oncogene addiction: setting the stage for molecularly targeted cancer therapy Genes Dev 21 2007 3214 3231 (Pubitemid 350277749)
81. I.B. Weinstein, and A. Joe Oncogene addiction Cancer Res 68 2008 3077 3080